Dual anti-PD-(L)1/TGF-β inhibitors in cancer immunotherapy – Updated

Karami, Z; Mortezaee, Keywan; Majidpoor, Jamal

doi:10.1016/j.intimp.2023.110648

Cited by 4 publications

(1 citation statement)

References 70 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Besides WNT/β-catenin, the activity of TGF-β signaling is also contributed to the stemness of tumor cells and cancer resistance to ICI therapy. Bispecific antibodies against TGF-β and PD-L1 are developed, and impressive responses are for PD-L1 high platinum refractory NSCLC patients [ 92 ].…”

Section: Combination Of Wnt/β-catenin Inhibitors With Anti-pd-1/pd-l1mentioning

confidence: 99%

WNT/β-catenin regulatory roles on PD-(L)1 and immunotherapy responses

Mortezaee

2024

Clin Exp Med

Self Cite

View full text Add to dashboard Cite

Dysregulation of WNT/β-catenin is a hallmark of many cancer types and a key mediator of metastasis in solid tumors. Overactive β-catenin signaling hampers dendritic cell (DC) recruitment, promotes CD8+ T cell exclusion and increases the population of regulatory T cells (Tregs). The activity of WNT/β-catenin also induces the expression of programmed death-ligand 1 (PD-L1) on tumor cells and promotes programmed death-1 (PD-1) upregulation. Increased activity of WNT/β-catenin signaling after anti-PD-1 therapy is indicative of a possible implication of this signaling in bypassing immune checkpoint inhibitor (ICI) therapy. This review is aimed at giving a comprehensive overview of the WNT/β-catenin regulatory roles on PD-1/PD-L1 axis in tumor immune ecosystem, discussing about key mechanistic events contributed to the WNT/β-catenin-mediated bypass of ICI therapy, and representing inhibitors of this signaling as promising combinatory regimen to go with anti-PD-(L)1 in cancer immunotherapy. Ideas presented in this review imply the synergistic efficacy of such combination therapy in rendering durable anti-tumor immunity.

show abstract

Section: Combination Of Wnt/β-catenin Inhibitors With Anti-pd-1/pd-l1mentioning

confidence: 99%